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1607-551X/Copyright ª 2014, KaohsiuAbstract Erectile dysfunction (ED) and urinary incontinence after bilateral nerve-sparing
radical prostatectomy (BNSRP) still remain major causes of morbidity. Phosphodiesterase type
5 inhibitors (PDE5-Is) have a role in the treatment of ED after BNSRP. Several studies in patients
with ED and lower urinary tract symptoms demonstrated that PDE5-Is could improve both erec-
tile function and urinary symptoms. The aim of this study was to compare the efficacies of two
dosing regimens of 20 mg tadalafil (on-demand and 3 times per week) and to assess the role of
tadalafil in recovery of erectile function and continence after BNSRP. We conducted a single-
center, prospective, randomized controlled trial of three times per week versus on-demand ta-
dalafil 20 mg and a control group after BNSRP. A total of 129 preoperatively potent and conti-
nent patients were included in the study. The patients were evaluated at 6 weeks and 12
months postoperatively for erectile function and continence status. There was no significant
difference between all three groups with respect to erectile function at 6 weeks after the sur-
gery. Twelve months after the surgery, the International Index of Erectile Function score was
significantly higher in the group using tadalafil 20 mg three times per week. However, there
was no significant difference between the treated groups and the control group with respect
to the continence status at 12 months after the surgery. There was no correlation between in-
continence and ED after the surgery in all groups. Tadalafil 20 mg three times per week is an
efficacious and well-tolerated treatment option for ED after BNSRP. Treatment with 20 mgeclare no conflicts of interest.
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Radical prostatectomy and tadalafil 91tadalafil either three times per week or on demand cannot improve continence recovery after
BNSRP compared with the control group.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Radical prostatectomy (RP) is a commonly performed pro-
cedure for patients with clinically localized prostate cancer
and a life expectancy of at least 10 years [1]. The number
of RPs has been increasing annually, and currently many
patients are treated at younger ages. The most common
long-term complications of this procedure are urinary in-
continence (UI) and erectile dysfunction (ED), which
significantly affect quality of life after surgery [2].
Phosphodiesterase type 5 inhibitors (PDE5-Is), such as
tadalafil, sildenafil, and vardenafil, are the recommended
first-line treatment for ED [3] and are currently used to
repair erectile dysfunction after RP; nevertheless, a
treatment for continence rehabilitation is still lacking.
Several studies have demonstrated that cyclic guanosine
monophosphate (cGMP) and the cGMP-dependent protein
kinase-1 are expressed in the prostate, bladder, and urethra
[4,5]. Currently, the anatomical site of action of PDE5-Is in
theurinary system is unknown. Evaluation of urinary function
in patients treated with tadalafil after RP allows us to assess
whether or not positive activity of PDE5-Is on the lower uri-
nary tract can be increased even in the absence of the
prostate gland. Management of PDE5-Is may increase pelvic
blood flow and oxygen supply, with a beneficial effect on
sphincter function. There are few data on the possible ef-
fects of PDE5-Is on continence recovery after bilateral nerve-
sparing radical prostatectomy (BNSRP) in the literature [6].
The aim of our study is to evaluate the influence of three
times per week and on-demand tadalafil administration to
analyze rehabilitation of erectile function and continence
after BNSRP.Materials and methods
Patients were enrolled between June 2006 and September
2010 in one center in Turkey. All patients signed written
informed consent forms prior to the study; this study was
conducted in accordance with the ethical principles of the
Declaration of Helsinki (1996) and Good Clinical Practice
guidelines (1997), and was approved by the local ethics
committee.
The present study included 129 patients with prostate
cancer who underwent retropubic BNSRP with or without
lymph node dissection. Indication for preservation of neu-
rovascular bundles was based on the characteristics at
diagnosis [prostate-specific antigen (PSA) < 10 ng/mL, cT1-
T2a disease, and a biopsy Gleason score  3 þ 4].
After catheter removal, 2 weeks after surgery, patients
were divided into three groups: patients using Tadalafil
20 mg three times per week (Group 1), patients using
tadalafil 20 mg on demand (Group 2), and patients not using
PDE5-Is (Group 3). For randomization, the Number CruncherStatistical System 2007 program (Istanbul, Turkey) was
used. All patients were strongly recommended to attempt
sexual intercourse as soon as possible after catheter
removal, and all patients were strongly encouraged to start
pelvic floor muscle exercise in order to improve urinary
continence. Patients in Groups 1 and 2 received the pro-
tocols for 12 months following the removal of the urethral
catheter. Patients were instructed to take their ‘on-de-
mand’ dose 1 hour before sexual activity and ‘three times a
week’ dose 1 hour before bedtime.
All patients were stratified by complete preoperative
clinical and functional data, including age, body mass
index, preoperative PSA, smoking, alcohol consumption,
and presence of comorbidities (e.g., diabetes mellitus,
hypertension, and coronary arterial disease) (Table 1).
Preoperatively, all patients were evaluated for erectile
function based on the International Index of Erectile
Function (IIEF-6) [7]. Urinary function was evaluated by the
International Prostate Symptom Score [8,9], and conti-
nence status was evaluated by the International Consulta-
tion on Incontinence QuestionnaireeShort Form (ICIQ-SF)
[10,11]. The Beck Depression Index (BDI) form was used
for psychological evaluation [12]. Patients were evaluated
at 6 weeks and 12 months after the surgery.
Patients with moderate or severe ED prior to the surgery
were excluded from the study, and all patients had a steady
sexual partner. Patients were fully continent prior to the
surgery. Other exclusion criteria were as follows: any disor-
der that could affect the individuals’ ability to have sexual
intercourse, history of other malignancy, and a history of
pelvic surgery or pelvic radiotherapy. In addition, the pa-
tients who had received any treatment for ED or inconti-
nence, such as androgens, antiandrogens, 5a-reductase
inhibitors, and anticholinergic medications, were excluded.
Other exclusion criteria included hypersensitivity to tadalafil
and being unable to complete the questionnaires.
SPSS version 17 for Window (SPSS Inc., Chicago, IL, USA)
was used for statistical analysis. Demographic factors and
potential confounding variables were compared between
treatment groups using Chi-square tests for categorical
variables. Preoperative urinary, erectile, and continence
functions were analyzed according to different treatment
arms such as analysis of variance (ANOVA) and Krus-
kaleWallis test. We assessed the significance of erectile
function and continence decline (preoperative) and sub-
sequent recovery (6 weeks vs. 12 months) by t test for
paired samples. Differences between the three groups were
calculated by an ANOVA test.Results
During this study period, 152 patients were operated, 129
screened, and 112 randomized: 38 (33.9%) patients to
Table 1 Baseline data of groups.
Group 1 (n Z 38) Group 2 (n Z 40) Group 3 (n Z 34) p
Age (y) 62.63 (50e72) 62.95 (54e72) 63.52 (52e74) 0.888a
Total PSA (ng/mL) 7.26  2.41 6.20  1.97 6.19  2.48 0.237b
BMI (kg/m2) 27.6  3.4 26.3  3.1 26.7  2.9 0.367b
Diabetes mellitus (n) 6 6 6 0.665c
Hypertension (n) 6 4 8 0.665c
Cardiovascular disorder (n) 12 6 4 0.665c
Smoker (n) 16 16 12 0.665c
Alcohol consumption (n) 3 7 14 0.665c
ANOVA Z analysis of variance; BMI Z body mass index; PSA Z prostate-specific antigen.
a ANOVA test.
b KruskaleWallis test.
c Chi-square test.
92 L. Canat et al.tadalafil three times per week (Group 1), 40 (35.7%) pa-
tients to tadalafil on demand (Group 2), and 34 (30.3%)
patients to the control group (Group 3). Overall, eight
(21.05%) patients in Group 1, four (10%) patients in Group 2,
and five (14.7%) patients in Group 3 discontinued the study.
The mean age was 63 years (range: 50e74 years), and
the mean preoperative PSA was 6.55 ng/mL (range:
3.8e9.7 ng/mL). A total of 24 patients were pT2a, three
were pT2b, and 85 were pT2c in the definitive pathologic
stage. The definitive Gleason score was 5 in 11 cases, 6 in 36
cases, 7 in 57 cases, and 8 in eight cases. Baseline char-
acteristics were similar between the three groups, and
regarding the parameters that might be associated with ED
(body mass index, smoking and alcohol consumption, and
presence of comorbidities including diabetes mellitus, hy-
pertension, and coronary arterial disease) we found no
statistically significant difference between all three groups
(Table 1). The preoperative mean IIEF-6 score, mean In-
ternational Prostate Symptom Score, mean ICIQ-SF score,
and mean BDI score are demonstrated in Table 2. The three
groups did not show any significant difference for all pre-
operative scores.
There were no significant differences between all three
groups with respect to the IIEF-6 scores at 6 weeks after the
surgery. However, 12 months after the surgery, the IIEF-6
score was significantly higher in Group 1. There were no
significant differences between Groups 2 and 3 in the 12th
month. Urinary continence analysis results of Group 1 were
statistically significantly different from those of the other
groups at 6 weeks after the surgery; the ICIQ-SF score wasTable 2 Preoperative IIEF, ICIQ-SF, IPSS, and BDI scores of grou
Group 1 (n Z 38) Group 2
IIEF score 26.15  2.79 24.75
ICIQ-SF score 0 0
IPSS score 14  5.4 17.93
BDI score 3.21  2.76 2.80
ANOVAZ analysis of variance; BDIZ Beck Depression Index; ICIQ-SFZ
Form; IIEF Z International Index of Erection Function; IPSS Z Intern
a ANOVA test.
b All patients were fully continent.
c KruskaleWallis test.significantly higher in Group 1. Nevertheless, there were no
significant differences among the groups at 12 months after
the surgery. When erectile function and continence status
were evaluated together, there were no correlation at 6
weeks and 12 months after the surgery. Psychological
analysis indicated that the BDI score was not different
among the groups (Table 3).
In none of the groups, medication was required to be
stopped due to adverse events. The most frequently re-
ported treatment-emergent adverse events include flush-
ing, headache, dizziness, and dyspepsia (Table 4).Discussion
ED and UI continue to be significant complaints among men
undergoing RP, despite using the nerve-sparing technique.
The incidence of complete ED has been reported to be
26e100% and partial ED 16e48% [13]. The most appropriate
preservation of erectile function after RP represents one of
the major difficulties for practicing urologists [14]. PDE5-Is
are more commonly used in penile rehabilitation programs
than in other treatment alternatives [15]. The influence
and adverse events of PDE5-Is used to treat ED after BNSRP
have been largely studied. However, varying efficacy has
been reported, with no final evidence to promote the
optimal treatment strategy. There is no consensus or
guidelines on their use at present.
Penile rehabilitation therapy has become a subject of
intense concern over the past decade. Schwartz et al [16]ps.
(n Z 40) Group 3 (n Z 34) p
 4.02 24.76  3.38 0.362a
0 b
 5.19 16  10.86 0.571a
 2.09 2.11  2.26 0.276c
International Consultation on Incontinence QuestionnairedShort
ational Prostate Symptom Score.
Table 3 Postoperative 6th week and 12th month IIEF, ICIQ-SF, and BDI scores of groups.
Group 1 (n Z 38) Group 2 (n Z 40) Group 3 (n Z 34) p
6th wk IIEF score 15.52  7.49 15.35  6.08 14.76  5.29 0.933a
12th mo IIEF score 19.89  5.90 15.8  6.97 13.47  5.66 0.011a
6th wk ICIQ-SF score 7.15  5.41 3.85  2.75 3.35  2.17 0.006b
12th mo ICIQ-SF score 4.26  3.88 3.25  3.22 2.94  1.91 0.766b
6th wk BDI score 4.31  3.26 3.70  1.65 3.52  2.21 0.625b
12th mo BDI score 3.89  3.84 3.50  1.60 3.94  1.91 0.502**
ANOVAZ analysis of variance; BDIZ Beck Depression Index; ICIQ-SFZ International Consultation on Incontinence QuestionnairedShort
Form; IIEF Z International Index of Erection Function.
a ANOVA test.
b KruskaleWallis test.
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after RP may conserve intracorporeal smooth muscle con-
tent. Several well-designed studies have supported the use
of PDE5-Is for penile rehabilitation after this trial [17].
None of these studies have demonstrated higher efficacy of
penile rehabilitation with PDE5-Is as compared to the on-
demand administration schedule. Pavlovich et al [18]
demonstrated that erectile functions did not differ be-
tween patients using sildenafil either nightly nor on demand
after BNSRP. Another prospective, randomized study
demonstrated that on-demand vardenafil was found to be
more efficient than its daily use in advancing erectile
function [19]. In our recent study, tadalafil administered
three times per week was found to be more effective than
its on-demand use in improving erectile function after
BNSRP. We chose tadalafil among all PDE5-Is in our study.
Because the longer half-life of tadalafil preferences to this
drug the suitable pharmacokinetic profile for its use in
penile rehabilitation. The Scheduled Use versus on-demand
Regimen Evaluation (SURE) study, which included 4262
patientsdthe largest study population, indicated that
tadalafil is effective and well tolerated irrespective of
whether it is used on demand or three times per week.
Furthermore, a large number of patients (42.2%) preferred
the three times per week treatment [20].
As we mentioned previously, post RP, ED is a common
problem. This wide range can be explained by the differing
forms of consideration in clinical trials. There are signifi-
cant differences with respect to the surgical technique
used as well as the number of surgeons involved. BNSRP was
performed in all patients; however, although previous
studies involved many surgeons, in our study all operations
were performed by only one surgeon.Table 4 Adverse events of treatment groups.
Group 1
(n Z 38)
Group 2
(n Z 40)
pa
n (%) n (%)
No adverse event 22 (57.8) 30 (75) 0.737
Flushing 6 (15.8) 4 (10) 0.737
Headache 6 (15.8) 4 (10) 0.737
Dizziness 2 (5.3) 0 (0) 0.737
Dyspepsia 2 (5.3) 2 (5) 0.737
a Chi-square test.In the current study, drug administration began imme-
diately after catheter removal and we suggested that pa-
tients in the on-demand group might begin sexual
intercourse 4 weeks after the surgery.
The effects of PDE5-Is in UI has been a current ıssue
as well as ED. It is known that elevated levels of cGMP
may inhibit smooth muscle apoptosis or collagen depo-
sition. Effects of vardenafil on bladder overactivity were
derived from preclinical studies on human and rat
bladder smooth muscle cells [21]. Here, we investigated
the effects of tadalafil administration on not only erec-
tile function but also urinary continence status after
BNSRP. Thus, considering all these points, our trial is one
of the rare studies in the literature that evaluated these
two factors together in a penile rehabilitation program
after BNSRP.
The neurotrophic impact of PDE5-Is may be notable in
the afferent suburothelial plexus of the trigon and bladder
neck [22]. Besides, membranous urethral blood flow may be
one of the targets of the PDE5-I-mediated sphincter
contraction [23]. Age, obesity, and diabetes mellitus can
also be taken into account as markers of patients’ vascular
and neurogenic statuses. These factors might be associated
with poor pelvic vascular status, thus leading to a reduction
in pelvic and sphincteric blood flow. All these variables
were analyzed in detail in our study and a homogeneous
distribution among the groups was maintained.
UI is a well-known complication of RP and occurs in
2e87% of patients after surgery [24]. Moreover, it remains
one of the most boring sequelae influencing quality of life
after RP and affects 1e25% of patients [25,26].
There are several studies in the literature on the treat-
ment of post-RP incontinence. Several studies have inves-
tigated the influence of behavioral therapy on UI after RP;
limited data are available on the impact of medical therapy
on UI after the surgery [27,28]. One of the agents used in
medical treatment of UI after RP includes PDE5-Is, and the
number of studies dealing with this subject is increasing.
Gacci et al [6] demonstrated that the strong correlation
between continence and sexual recovery in vardenafil
nightly group compared with the placebo group after BNSRP
with small number of patients. In our study, which enrolled
112 patients, no correlation was observed between conti-
nence and erectile function at 12 months after the surgery.
Another study interestingly showed ED prior to RP as a
prognostic factor for UI after surgery [29]. Our study did not
evaluate this situation because patients with moderate or
94 L. Canat et al.severe ED prior to the surgery were excluded from the
study.
Urodynamic studies should provide beneficial informa-
tion about UI. However, urodynamic testing is invasive,
difficult, and expensive. Therefore, validated question-
naires can be used to record the incontinence. The ICIQ-SF
was recommended by the International Continence Society
[30] and validated in a Turkish population in 2004 [31]. The
consideration of its internal consistency demonstrated that
the ICIQ-SF provides repeatable and reliable data [30]. We
used this form to assess the urinary continence status after
BNSRP. There was no significant difference between the
treated groups and the control group with respect to the
ICIQ-SF scores at 12 months after the surgery, unlike some
previous studies. However, incontinence was significantly
higher in the three times per week group than in the on-
demand or control group at 6 weeks after the surgery. We
could not explain this interesting finding with any patho-
physiological mechanism.
In our study, both routes of administration of tadalafil
were well tolerated. Headache was the most common side
effect, along with flushing. A meta-analysis also revealed
that headache was the most frequently reported adverse
effect of PDE5-Is [32].
A limitation of our study is the lack of a placebo arm.
Furthermore, the duration of the current trial was 12
months. Additionally, drug administration began immedi-
ately after the surgery (after removal of catheter).
Therefore, not all patients would experience post-RP ED
and incontinence. Thus, the consideration of the efficacy of
tadalafil for ED and incontinence might have some biases
due to inclusion of some patients without ED and inconti-
nence prior to the surgery. Despite these limitations, the
present study represents a relatively large prospective
report trying to evaluate the association between different
routes of PDE5-I administration and erectile functioneuri-
nary continence recovery in patients treated with BNSRP.Conclusion
ED and UI will continue to be important problems for pa-
tients undergoing RP. PDE5-Is have become the first-line
treatment for ED after localized treatment for prostate
cancer. However, there is not sufficient evidence to
recommend the use of PDE5-Is for post-RP incontinence. We
conclude that tadalafil 20 mg three times per week is an
efficacious and well-tolerated treatment option for ED post
RP. However, neither tadalafil on demand nor tadalafil
three times per week can improve continence recovery
after BNSRP. For practical application of PDE5-Is to treat
post-RP ED and incontinence, more randomized, placebo-
controlled clinical trials with a larger population of patients
are required, to investigate variables such as time of initi-
ation of treatment, duration of treatment, dosage
required, and selection of the most efficacious drug.References
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